Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AstraProst (also known as [211At]AstraProst) is a preclinical-stage targeted alpha therapy (TAT) radiopharmaceutical being developed by TetraKit Technologies in collaboration with the University of Copenhagen and Rigshospitalet. It is designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). AstraProst consists of a glutamate-urea-lysine pharmacophore that targets prostate-specific membrane antigen (PSMA), radiolabeled with the alpha-emitting radionuclide astatine-211 (211At) using TetraKit's proprietary tetrazine ligation (click chemistry) platform. In preclinical studies, AstraProst demonstrated high binding affinity and internalization in PSMA-positive LNCaP cells, leading to delayed tumor growth and prolonged survival in tumor-bearing mice.
| Indication | Highest phase | Status |
|---|---|---|
| metastatic castration-resistant prostate cancer (mCRPC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AstraProst.
Work on AstraProst? Claim this page to correct or add information. Claim this page